MALT1-IN-13

MALT1-IN-13 (compound 10m) is inhibitor for mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), which to binds MALT1 protease covalently and irreversibly, inhibits MALT1 with the IC50 of 1.7 μM. MALT1-IN-13 inhibits proliferation against ABC-DLBCL and induces apoptosis in ABC-DLBCL HBL1. MALT1-IN-13 regulates mTOR and PI3K-Akt pathways[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; MALT1

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/malt1-in-13.html

Solubility

10 mM in DMSO

Smiles

O=C1C(S2)=C(N=C(N1C3=CC(OC)=CC=C3OC)CBr)N(C4=CC=CC(Cl)=C4)C2=S

Molecular Formula

C20H15BrClN3O3S2

Molecular Weight

524.84

References & Citations

[1]Liang X, et al., Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidin-7 (6H) -one" Scaffold for the Treatment of B Cell Lymphoma. J Med Chem. 2024 Feb 22;67 (4) :2884-2906.|[2]Liang X, et al., Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidin-7 (6H) -one" Scaffold for the Treatment of B Cell Lymphoma. J Med Chem. 2024 Feb 22;67 (4) :2884-2906.